Search Results - "Yoshimura, Akihiro"

PubPharm (6)

1

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

in: Nature communications | Vol. 11, No. 1 (2020), p. 4607

by Wang, R. | Yamada, T. | Kita, K. | +24

2

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer

in: Cancer medicine | Vol. 8, No. 4 (2019), p. 1521-1529

by Yamada, T. | Hirai, S. | Katayama, Y. | +14

3

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

in: Nature communications | Vol. 10, No. 1 (2019), p. 259

by Taniguchi, H. | Yamada, T. | Wang, R. | +21

4

Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis

in: Thoracic cancer | Vol. 10, No. 3 (2019), p. 557-563

by Yoshimura, A. | Yamada, T. | Tsuji, T. | +7

5

An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer

in: Medicine | Vol. 97, No. 40 (2018), p. e12660

by Yoshimura, A. | Uchino, J. | Tanimura, K. | +12

6

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations

in: BMC cancer | Vol. 18, No. 1 (2018), p. 1241

by Yoshimura, A. | Yamada, T. | Okura, N. | +11

1
[1]